### Autologous Bone Marrow-derived Mesenchymal Stem Cells versus Tensionfree Vaginal Tape for Treatment of Female Stress Urinary Incontinence

### A Thesis

Submitted for partial fulfillment of MD Degree in Obstetrics & Gynecology

#### By Rania Hassan Mostafa

M.B.,B.Ch. Ain Shams University, 2008 M.Sc. Obstetrics & Gynecology, Ain Shams University, 2013 Assistant lecturer of Obstetrics & Gynecology, Ain Shams University

Under supervision of

### Prof. Mohamed Adel El-Nazer

Professor of Obstetrics & Gynecology Faculty of Medicine, Ain Shams University

### Assist. Prof. Abdel-Latif Galal El-Kholy

Assistant Professor of Obstetrics & Gynecology Faculty of Medicine, Ain Shams University

### Assist. Prof. Mostafa Fouad Gomaa

Assistant professor of Obstetrics & Gynecology Faculty of Medicine, Ain Shams University

### Dr. Fatma Abdel Kereem Abu Zahra

PhD Molecular Biology & Tissue Culture, Ain Shams University

Faculty of Medicine Ain Shams University 2017

## <u>Acknowledgements</u>

I would like to express my sincere gratitude to Prof. Dr/ Mohamed Adel El-Nazer, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his continuous encouragement & supervision all through the whole work.

Thanks are due to Assist. Prof. Dr/ Abdel-Latif Galal El-Kholy, Assistant professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, for his invaluable support & cooperation.

I am also deeply grateful to Assist. Prof. Dr/ Mostafa Fouad Gomaa, Assistant professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for dedicating much of his precious time & knowledge to accomplish this work.

Also, thanks are due to Dr/ Fatma Abdel Kereem Abu Zahra, PhD Molecular Biology & Tissue Culture, Ain Shams University, for her kind efforts all through the whole work.

Last but not least I would like to express my thanks and gratitude to My Family, friends, & colleagues, for their continuous encouragement & support.

Rania Hassan Mostafa -2017

# Table of Contents

List of abbreviations	I
List of tables	IV
List of figures	V
Protocol	VII
Introduction	1
Aim of the Work	3
Review of literature:	
Chapter One: Urinary Continence	4
<ul><li>Chapter Two: Urinary Incontinence</li><li>Chapter Three: Management of Female</li></ul>	
Urinary Incontinence	
Chapter Four: Stem Cells Overview	42
Patients & methods	54
Results	68
Discussion	82
Summary	94
Conclusion	99
Recommendations	100
References	101
Appendices	117
Arabic summary	—

# Tist of Abbreviations

ACOG ......American College of Obstetricians & Gynecologists

ACP.....American College for Physicians

ADRC ......Adipose-derived regenerative cells

**ADSCs.....**Adipose-derived stem cells

ALPP.....Abdominal leak point pressure

**bFGF.....**Basic fibroblast growth factor

**BM....**Bone marrow

BMI.....Body mass index

BMSCs......Bone marrow-derived stem cells

CLPP...... Cough leak point pressure

**CMG** ......Cystometrography

**CRF....** Case record form

CT .....Computed Tomography

**DM** .....Diabetes Mellitus

**DSD**.....Detrusor sphincter dyssynergia

EDTA.....Ethylene-diamine-tetraacetic acid

EMG .....Electromyography

**ESC** .....Embryonic stem cells

EUS .....External urethral sphincter

**FDA.....**Food & Drug Administration **HGF** ......Hepatocyte growth factor **ICIO-UI SF**International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form **ICS** .....International Continence Society **IFN-γ....**Interferon-γ **IGF-1.....**Insulin-like growth factor-1 **iPSC** .....Induced pluripotent stem cells I-QOL ......Incontinence Quality of Life Instrument Score **ISD** .....Intrinsic sphincter deficiency **IUGA.....**International Urogynecological Association KHQ.....Kings Health Questionnaire LPP .....Leak point pressure **MDSCs.....** Muscle-derived stem cells MNCs......Mononuclear cells MRI......Magnetic resonance imaging MS.....Multiple Sclerosis MSCs.....Mesenchymal stem cells MUCP......Maximum urethral closure pressure MUS......Midurethral slings NICE.......National Institute for Health & Clinical

Excellence

**OAB** ......Overactive bladder

Pabd ......Abdominal pressure

Pdet .....Detrusor pressure

**PFMT.....**Pelvic floor muscle training

**PP** .....Per protocol

Pves .....Intravesical pressure

**PVR.....**Postvoid residual urine volume

Qmax.....Maximum flow rate

SD.....Standard deviation

**SDF-1**.....Stem cell-derived factor-1

**SEM** ......Standard error of mean

SIS.....Small intestinal submucosa

**SLE** .....Systemic lupus erythematosus

SUI .....Stress urinary incontinence

**TVT.....**Tension-free vaginal tape

TVT-O ......Obturator approach for midurethral sling

**USCs** ......Urine-derived stem cells

**UPP** ...... Urethral pressure profile

**VLPP** ..... Valsalva leak point pressure

WMA .......World Medical Association

# Tist of Tables

No.	Content	Page
1	Potentially-reversible Causes of Incontinence	16
2	Characteristics of patients in both study groups	70
3	ICIQ-UI SF score in both study groups	71
4	Per protocol (PP) analysis for the percentage of patients with positive cough test in both study groups	73
5	MUCP in both study groups	75
6	ALPP in patients with leakage in both study groups	77
7	I-QOL in both study groups	79

# List of Figures

No.	Content	Page
1	The female urethra- transverse section	6
2	The female urethra - internal & external sphincter	6
3	Mechanism of storage and voiding reflexes	9
4	Urethral sphincter supported by levator ani	10
5	Stress cystometry	25
6	Burch colposuspension	32
7	Pubovaginal sling	34
8	TVT	35
9	TVT materials	35
10	Transobturator sling	36
11	The transobturator tape and the helical needles	36
12	Embryonic stem cells & Stem cell therapy	43
13	Duet Sensic Mediwatch®	58
14	Cystometry showing VLPP 30cmH <sub>2</sub> O in a patient with ISD	59

15	UPP showing MUCP 13cmH <sub>2</sub> O in a patient with ISD	59
16	BM aspiration	61
17	Mononuclear cells - Day 2	63
18	Fibroblast-like shape of mesenchymal stem cells	64
19	MSCs showing confluence	64
20	Flowchart for the whole study	69
21	Mean ICIQ-UI SF score in both study groups	72
22	Per protocol analysis for the percentage of patients with positive cough test in both study groups	74
23	Mean MUCP in both study groups	<b>7</b> 6
24	Mean ALPP in patients with leakage in both study groups	78
25	Mean I-QOL in both study groups	80

### Autologous Bone Marrow-derived Mesenchymal Stem Cells versus Tension-Free Vaginal Tape for Treatment of Female Stress Urinary Incontinence

Protocol of a study submitted for the partial fulfillment of MD Degree in Obstetrics & Gynecology

### By **Rania Hassan Mostafa**

M.B.B.CH. Ain Shams University 2008 Msc. Obstetrics & Gynecology Ain Shams University 2013 Assistant lecturer of Obstetrics & Gynecology Ain Shams University

Under supervision of
Prof. Mohamed Adel El-Nazer
Professor of Obstetrics & Gynecology
Ain Shams University

Assist. Prof. Abdel-Latif Galal El-Kholy
Assistant professor of Obstetrics & Gynecology
Ain Shams University

**Dr. Mostafa Fouad Gomaa**Lecturer of Obstetrics & Gynecology
Ain Shams University

Dr. Fatma Abdel Kereem Abu Zahra
PhD Molecular Biology & Tissue Culture
Ain Shams University



## **Introduction:**

Urinary incontinence is a significant health problem with considerable social and economic impact affecting over 200 million people worldwide (*Norton et al., 2006*). The exact prevalence of urinary incontinence is difficult to estimate; partly due to variations in defining the degree & frequency, & the other problem is that it represents a social stigma; so many women don't seek medical evaluation & the condition is under diagnosed & underreported (*Vasavada et al., 2013*).

Urinary incontinence is defined by the International Continence Society as the involuntary loss of urine that represents a hygienic or social problem to the individual (Abrams et al., 2002). In the study by Hannestad et al., the commonest type of female urinary incontinence was the stress urinary incontinence (SUI) representing 50% of patients, while 11% had urge incontinence, & 36% had mixed incontinence (Hannestad et al., 2000). Risk factors for SUI include increasing parity, advanced age, & obesity (Bump et al., 1998). Trauma to the pelvic floor musculature, connective tissue or nerves mostly after vaginal delivery becomes the most important risk factor for development of SUI (Meyer et al., 1998). SUI may be due to urethral hypermobility, or intrinsic sphincter deficiency (ISD), or both (McGuire et al., 1976). In fact; these mechanisms

represent two extremes of the spectrum of SUI; with the patients having varying degrees of both disorders (*Kayigil et al.*, 1999).

Attempts to treat SUI with pharmaceuticals, including alpha-agonists have not been highly successful (Radley et al., 2001). Short-term success has been achieved with injectable bulking agents such as polytetrafluoroethylene, bovine collagen, silicone, carbon beads, and autologous ear chondrocytes (Nikolavsky et al., 2010). However, long-term these treatments complications of included chronic inflammatory reactions, foreign body giant cell responses, periurethral abscesses, erosion of the bladder and urethra, particle migration, obstruction of urinary tract causing retention, and even pulmonary embolism (Sweat et al., 1999). Surgical therapy seems to be one of the options for achieving long-term continence with the tension-free vaginal tape becoming the most popular procedure for SUI (Yang et al., 2013). However, surgery for SUI sometimes causes postoperative voiding difficulty and infection, and treatments are still very difficult in the patients with recurrent SUI after anti-incontinence surgery because primary intrinsic sphincter deficiency can't be remedied directly (*Novara et al.*, 2007).

A novel therapeutic strategy for patient with SUI is needed to achieve a long term & stable curative result (*Song et al.*, 2009).

Stem cell therapy represents a paradigm shift in treatment of many disorders, as these cells are characterized by their ability to self-renew & to differentiate along multiple lineage pathways (Mizuno, 2009). Stem cells are either embryonic stem cells or adult stem cells (Mizuno, 2009). The use of embryonic stem cells is somehow limited; due to ethical considerations, increased tumorigenicity potential, & regulations (*Edwards*, 2007). On the other hand; autologous adult stem cells are immunocompatible, & there're no ethical issues related to their use (Yang et al., 2013; Mizuno, 2009). Some safety concerns are still raised with the use of adult stem cells as regards tumorigenicity; either due to non-target organ seeding or in vitro culture of cells; however these initial concerns flawed, as experimental & clinical data have been coming out with such complication not reported so far (Sanchez PL et al., 2006). This was concluded from systematic reviews of previous stem cell studies; like the systematic review & meta-analysis by Abdel-Latif A et al. on adult bone marrow derived cells for cardiac repair; which included 18 studies, involving 999 patients & supports safety of bone marrow derived cells transplantation (Abdel-Latif A et al., 2007). Another systematic review by Martin-Rendon E et al. provides systematic assessment of the safety and efficacy of autologous bone marrow-derived stem cell transplantation in acute myocardial infarction based on clinical evidence. Thirteen trials with total 811 patients were

Rendon E et al., 2008). As in the field of urology, a critical review by Lin & Lue on stem cell therapy for stress urinary incontinence included preclinical & clinical studies from the year 2002 till the year 2011, & no malignant potential or other harmful effects evolved (Lin & Lue, 2012). Adult mesenchymal stem cells (MSCs) could be obtained from bone marrow (Barry et al., 2004), adipose tissue (Zuk et al., 2002), skeletal muscle (Lu et al., 2009), hair follicle (Drewa, 2008), & urine (Zhang et al., 2008; Bharadwaj et al., 2011). As MSCs possess multilineage differentiation potential including skeletal & smooth muscles; these represent a promising option for sphincter regeneration; thus restoring structure & function of the urethral sphincter (Novara et al., 2007; Zhao et al., 2011).

In this study; we'll evaluate periurethral injection of autologous bone marrow-derived mesenchymal stem cells in comparison to tension-free vaginal tape as a therapy for female stress urinary incontinence due to intrinsic sphincter deficiency.

### 1. Aim of the work:

### 1.1. Research hypothesis:

Adult mesenchymal stem cells derived from bone marrow have the capability for self-renewal & differentiation

according to the surrounding medium into many different cell types including smooth muscle cells & skeletal muscle cells. This could be used to restore & maintain the structure & function of urethral sphincter; & thus provides an effective therapy for stress urinary incontinence due to intrinsic sphincter deficiency.

#### 1.2. Research question:

Whether periurethral injection of autologous bone marrow-derived mesenchymal stem cells cures or improves stress urinary incontinence due to intrinsic sphincter deficiency or not.

### 1.3. Primary outcome:

To measure efficacy of mesenchymal stem cell therapy compared to tension-free vaginal tape (TVT) in treatment of stress urinary incontinence; by: clinical examination (cough test, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form [ICIQ-UI SF][appendix III]) & urodynamic study before & after therapy each 3 months for one year (at 3m, 6m, 9m, 12m post-injection).

### 1.4. Secondary outcome:

To evaluate quality of life before & after therapy; By: The Incontinence Quality of Life (I-QOL) Instrument Score [appendix IV].